Trump Wins… But Elon Says Get Ready to Brace

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

Rupert Vessey Biography and Net Worth

EVP of Bristol-Myers Squibb

Rupert Vessey leads Research and Early Development, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. He also works closely with Business Development to identify external sources of innovation.

“My colleagues and I believe in the power of scientific innovation to change the course of human health,” says Rupert. “That kind of culture and dedication is my most powerful motivator when I come to work each day.”

Rupert joined BMS from Celgene, where he served as President of the company’s Research and Early Development organization. Prior to joining Celgene in 2015, Rupert spent ten years at Merck, where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at Merck, he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.

Rupert graduated from Oxford University in the United Kingdom with degrees in Physiological Sciences (M.A.), Clinical Medicine (B.M., B.Ch.) and a Doctor of Philosophy (D.Phil.) in Molecular Immunology. He is an elected Fellow of the Royal College of Physicians.

What is Rupert Vessey's net worth?: The estimated net worth of Rupert Vessey is at least $2.81 million as of May 3rd, 2023. Mr. Vessey owns 47,751 shares of Bristol-Myers Squibb stock worth more than $2,811,101 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Vessey may own. Learn More about Rupert Vessey's net worth.
How do I contact Rupert Vessey?: The corporate mailing address for Mr. Vessey and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Rupert Vessey's contact information.
Has Rupert Vessey been buying or selling shares of Bristol-Myers Squibb?: Rupert Vessey has not been actively trading shares of Bristol-Myers Squibb during the last ninety days. Most recently, Rupert Vessey sold 50,385 shares of the business's stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $67.06, for a transaction totalling $3,378,818.10. Following the completion of the sale, the executive vice president now directly owns 47,751 shares of the company's stock, valued at $3,202,182.06. Learn More on Rupert Vessey's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 6,901 shares worth more than $349,655.16. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Rupert Vessey Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2023	Sell	50,385	$67.06	$3,378,818.10	47,751
11/7/2022	Sell	45,910	$78.88	$3,621,380.80	57,079
3/16/2022	Sell	74,559	$69.25	$5,163,210.75
5/5/2021	Sell	30,546	$64.29	$1,963,802.34	45,139
11/23/2020	Sell	13,421	$61.34	$823,244.14	37,922
11/19/2020	Sell	57,591	$61.30	$3,530,328.30	46,142
6/15/2017	Sell	4,785	$120.18	$575,061.30	4,004
3/1/2017	Sell	4,000	$124.42	$497,680.00	778

Rupert Vessey Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $58.87

$57.62

$58.92

50 Day Range

MA: $53.66

$49.02

$59.82

2 Week Range

Now: $58.87

$39.35

$61.08

Volume

7,412,528 shs

Average Volume

14,364,571 shs

Market Capitalization

$119.40 billion

P/E Ratio

N/A

Dividend Yield

4.12%

Beta

0.44